Cullinan Oncology Stock Forecast - Naive Prediction

CGEM Stock  USD 12.22  0.36  2.86%   
The Naive Prediction forecasted value of Cullinan Oncology LLC on the next trading day is expected to be 10.51 with a mean absolute deviation of 0.41 and the sum of the absolute errors of 24.93. Cullinan Stock Forecast is based on your current time horizon. Although Cullinan Oncology's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Cullinan Oncology's systematic risk associated with finding meaningful patterns of Cullinan Oncology fundamentals over time.
  
As of the 22nd of November 2024, Payables Turnover is likely to drop to 0.07. In addition to that, Fixed Asset Turnover is likely to drop to 196.81. As of the 22nd of November 2024, Common Stock Shares Outstanding is likely to grow to about 42.3 M. Also, Net Income Applicable To Common Shares is likely to grow to about 134.3 M.

Cullinan Oncology Cash Forecast

Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Cullinan Oncology's financial statements to estimate their effects on upcoming price movements.
 
Cash  
First Reported
2012-03-31
Previous Quarter
115 M
Current Value
102.1 M
Quarterly Volatility
151 M
 
Yuan Drop
 
Covid
A naive forecasting model for Cullinan Oncology is a special case of the moving average forecasting where the number of periods used for smoothing is one. Therefore, the forecast of Cullinan Oncology LLC value for a given trading day is simply the observed value for the previous period. Due to the simplistic nature of the naive forecasting model, it can only be used to forecast up to one period.

Cullinan Oncology Naive Prediction Price Forecast For the 23rd of November

Given 90 days horizon, the Naive Prediction forecasted value of Cullinan Oncology LLC on the next trading day is expected to be 10.51 with a mean absolute deviation of 0.41, mean absolute percentage error of 0.27, and the sum of the absolute errors of 24.93.
Please note that although there have been many attempts to predict Cullinan Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cullinan Oncology's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).

Cullinan Oncology Stock Forecast Pattern

Backtest Cullinan OncologyCullinan Oncology Price PredictionBuy or Sell Advice 

Cullinan Oncology Forecasted Value

In the context of forecasting Cullinan Oncology's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Cullinan Oncology's downside and upside margins for the forecasting period are 6.86 and 14.17, respectively. We have considered Cullinan Oncology's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Market Value
12.22
10.51
Expected Value
14.17
Upside

Model Predictive Factors

The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Cullinan Oncology stock data series using in forecasting. Note that when a statistical model is used to represent Cullinan Oncology stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.
AICAkaike Information Criteria116.806
BiasArithmetic mean of the errors None
MADMean absolute deviation0.4087
MAPEMean absolute percentage error0.0252
SAESum of the absolute errors24.9297
This model is not at all useful as a medium-long range forecasting tool of Cullinan Oncology LLC. This model is simplistic and is included partly for completeness and partly because of its simplicity. It is unlikely that you'll want to use this model directly to predict Cullinan Oncology. Instead, consider using either the moving average model or the more general weighted moving average model with a higher (i.e., greater than 1) number of periods, and possibly a different set of weights.

Predictive Modules for Cullinan Oncology

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cullinan Oncology LLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cullinan Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
9.2612.9216.58
Details
Intrinsic
Valuation
LowRealHigh
11.4815.1418.80
Details
Bollinger
Band Projection (param)
LowMiddleHigh
12.3615.2418.12
Details
10 Analysts
Consensus
LowTargetHigh
22.3924.6027.31
Details

Other Forecasting Options for Cullinan Oncology

For every potential investor in Cullinan, whether a beginner or expert, Cullinan Oncology's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Cullinan Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Cullinan. Basic forecasting techniques help filter out the noise by identifying Cullinan Oncology's price trends.

Cullinan Oncology Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cullinan Oncology stock to make a market-neutral strategy. Peer analysis of Cullinan Oncology could also be used in its relative valuation, which is a method of valuing Cullinan Oncology by comparing valuation metrics with similar companies.
 Risk & Return  Correlation

Cullinan Oncology LLC Technical and Predictive Analytics

The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Cullinan Oncology's price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Cullinan Oncology's current price.

Cullinan Oncology Market Strength Events

Market strength indicators help investors to evaluate how Cullinan Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cullinan Oncology shares will generate the highest return on investment. By undertsting and applying Cullinan Oncology stock market strength indicators, traders can identify Cullinan Oncology LLC entry and exit signals to maximize returns.

Cullinan Oncology Risk Indicators

The analysis of Cullinan Oncology's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Cullinan Oncology's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting cullinan stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:
Check out Historical Fundamental Analysis of Cullinan Oncology to cross-verify your projections.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.84)
Return On Assets
(0.20)
Return On Equity
(0.27)
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.